Dmitry Balyasny’s Cytek Biosciences CTKB Stock Holding History

Dmitry Balyasny’s Portfolio CTKB Stock Details CTKB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$241K	Buy	+54,381	New	+$232K	﹤0.01%	2770
2024 Q3	–	Sell	-16,238	Closed	-$90.6K	–	2803
2024 Q2	$90.6K	Sell	16,238 -29,529	-65%	-$177K	﹤0.01%	2407
2024 Q1	$307K	Buy	45,767 +16,840	+58%	+$133K	﹤0.01%	2252
2023 Q4	$264K	Buy	28,927 +15,267	+112%	+$96.1K	﹤0.01%	2218
2023 Q3	$75.4K	Sell	13,660 -68,304	-83%	-$548K	﹤0.01%	2141
2023 Q2	$700K	Sell	81,964 -40,055	-33%	-$359K	﹤0.01%	1752
2023 Q1	$1.12M	Sell	122,019 -994	-0.8%	-$10.7K	﹤0.01%	1698
2022 Q4	$1.26M	Buy	+123,013	New	+$1.65M	﹤0.01%	1582

Other funds holding CTKB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Boston Partners Boston, Massachusetts $113B AUM 38.87% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return

TCM

Topline Capital Management Santa Monica, California $386M AUM 2.37% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Dmitry Balyasny's CTKB Position: Q2 2026 in Review

Dmitry Balyasny opened a new position in Cytek Biosciences (CTKB) in Q2 2026: 54,381 shares worth $241K. The stake represents ﹤0.01% of the portfolio and ranks #2770 among its holdings. This is a return to the name: Dmitry Balyasny previously reported a position in CTKB as recently as Q2 2024.

Dmitry Balyasny first reported a position in CTKB in Q4 2022 and has held it in 8 quarters since. The position peaked at $1.26M in Q4 2022. 154 funds tracked by Wall St. Rank hold CTKB as of Q2 2026.

Dmitry Balyasny held 54,381 shares of Cytek Biosciences worth $241K as of Q2 2026.
Cytek Biosciences was a new Dmitry Balyasny position in Q2 2026.
Cytek Biosciences made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #2770 holding.
Dmitry Balyasny first reported a position in Cytek Biosciences in Q4 2022 and has held it in 8 quarters since.
Dmitry Balyasny's Cytek Biosciences position peaked at $1.26M in Q4 2022.
154 funds tracked by Wall St. Rank held Cytek Biosciences as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.